The FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
New Brunswick, NJ January 21, 2025 Johnson & Johnson ( NYSE:JNJ) has finally got its breakthrough depression treatment, ...
The FDA approved Spravato for those battling depression and has seen little to no improvement from two types of ...